AR034538A1 - Compuesto diazabiciclico n-substituido, composicion farmaceutica que lo comprende y el uso de dicho compuesto en la fabricacion de un medicamento util en el control de la liberacion de neurotransmisores y otras afecciones en mamiferos - Google Patents
Compuesto diazabiciclico n-substituido, composicion farmaceutica que lo comprende y el uso de dicho compuesto en la fabricacion de un medicamento util en el control de la liberacion de neurotransmisores y otras afecciones en mamiferosInfo
- Publication number
- AR034538A1 AR034538A1 ARP000100393A ARP000100393A AR034538A1 AR 034538 A1 AR034538 A1 AR 034538A1 AR P000100393 A ARP000100393 A AR P000100393A AR P000100393 A ARP000100393 A AR P000100393A AR 034538 A1 AR034538 A1 AR 034538A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- carboxy
- covalent bond
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 241000124008 Mammalia Species 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000002858 neurotransmitter agent Substances 0.000 title 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 3
- 229910052736 halogen Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 2
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- USXYDBGSWSSTGE-OCAPTIKFSA-N (1s,5r)-3-(6-chloropyridazin-3-yl)-3,8-diazabicyclo[3.2.1]octane Chemical compound N1=NC(Cl)=CC=C1N1C[C@H](N2)CC[C@H]2C1 USXYDBGSWSSTGE-OCAPTIKFSA-N 0.000 abstract 1
- ZKTZNDDSSBHWTJ-UHFFFAOYSA-N 3-(6-chloropyrazin-2-yl)-3,8-diazabicyclo[3.2.1]octane Chemical compound ClC1=CN=CC(N2CC3CCC(N3)C2)=N1 ZKTZNDDSSBHWTJ-UHFFFAOYSA-N 0.000 abstract 1
- AFWQPVUHNZFYNY-UHFFFAOYSA-N 8-(6-chloropyrazin-2-yl)-3,8-diazabicyclo[3.2.1]octane Chemical compound ClC1=CN=CC(N2C3CCC2CNC3)=N1 AFWQPVUHNZFYNY-UHFFFAOYSA-N 0.000 abstract 1
- YOWRIWKBABNICR-UHFFFAOYSA-N 8-(6-chloropyridazin-3-yl)-3,8-diazabicyclo[3.2.1]octane Chemical compound N1=NC(Cl)=CC=C1N1C2CCC1CNC2 YOWRIWKBABNICR-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004967 formylalkyl group Chemical group 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005358 mercaptoalkyl group Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 230000003957 neurotransmitter release Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- -1 nitro, 5-tetrazolyl Chemical group 0.000 abstract 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto diazabicíclico N-substituido caracterizado porque es de fórmula (1) o una sal aceptable para uso farmacéutico del mismo, en el cual: V se selecciona del grupo formado por un enlace covalente y CH2; W se selecciona del grupo formado por un enlace covalente, CH2 y CH2CH2; X se selecciona del grupo formado por un enlace covalente y CH2; Y se selecciona del grupo formado por un enlace covalente, CH2 y CH2CH2; Z se selecciona del grupo formado por CH2, CH2CH2 y CH2CH2CH2; L1 se selecciona del grupo formado por un enlace covalente y (CH2)n; n es 1-5; R1 se selecciona del grupo formado por los restos de fórmulas (2) a (13); R2 se selecciona del grupo formado por hidrógeno, alcoxicarbonilo, alquilo, aminoalquilo, aminocarbonilalquilo, benciloxicarbonilo, cianoalquilo, dihidropiridin-3-ilcarbonilo, hidroxi, hidroxialquilo, fenoxicarbonilo y -NH2; R4 se selecciona del grupo formado por hidrógeno, alquilo y halógeno; R5 se selecciona del grupo formado por hidrógeno, alcoxi, alquilo, halógeno, nitro y -NH2; R6 se selecciona del grupo formado por hidrógeno, alquenilo, alcoxi, alcoxialcoxi, alcoxialquilo, alcoxicarbonilo, alcoxicarbonilalquilo, alquilo, alquilcarbonilo, alquilcarboniloxi, alquiltio, alquinilo, amino, aminoalquilo, aminocarbonilo, aminocarbonilalquilo, aminosulfonilo, carboxi, carboxialquilo, ciano, cianoalquilo, formilo, formilalquilo, haloalcoxi, haloalquilo, halógeno, hidroxi, hidroxialquilo, mercapto, mercaptoalquilo, nitro, 5-tetrazolilo, -NR7SO2R8, -C(NR7)NR7R8, -CH2C(NR7)NR7R8, -C(NOR7)R8, -C(NCN)R7, -C(NNR7R8)R8, -S(O)2OR7 y -S(O)2R7; y R7 y R8 se seleccionan independientemente del grupo formado por hidrógeno y alquilo; siempre que se excluyan los siguientes compuestos: 3-(6-cloro-3-piridazinil)-3,8-diazabiciclo[3.2.1]octano; 3-(6-cloro-2-pirazinil)-3,8-diazabiciclo[3.2.1]octano; 8-(6-cloro-3-piridazinil)-3,8-diazabiciclo[3.2.1]octano; y 8-(6-cloro-2-pirazinil)-3,8-diazabiciclo[3.2.1]octano; y con la condición adicional de que siempre que V y X sean cada uno un enlace covalente, W, Y y Z sean cada uno CH2; y L1 un enlace covalente, entonces R1 es distinto del resto de fórmula (4). Dichos compuestos forman parte de composiciones farmacéuticas y son usados en la fabricación de medicamentos útiles para el control selectivo de la liberación de neurotransmisores y otras afecciones en mamíferos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23983899A | 1999-01-29 | 1999-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034538A1 true AR034538A1 (es) | 2004-03-03 |
Family
ID=22903947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100393A AR034538A1 (es) | 1999-01-29 | 2000-01-28 | Compuesto diazabiciclico n-substituido, composicion farmaceutica que lo comprende y el uso de dicho compuesto en la fabricacion de un medicamento util en el control de la liberacion de neurotransmisores y otras afecciones en mamiferos |
Country Status (26)
| Country | Link |
|---|---|
| EP (2) | EP1147112B1 (es) |
| JP (1) | JP4676062B2 (es) |
| KR (1) | KR20010101725A (es) |
| CN (2) | CN1636996A (es) |
| AR (1) | AR034538A1 (es) |
| AT (2) | ATE394401T1 (es) |
| AU (1) | AU773795B2 (es) |
| BG (1) | BG105836A (es) |
| BR (1) | BR0007664A (es) |
| CA (1) | CA2361525C (es) |
| CO (1) | CO5150231A1 (es) |
| CZ (1) | CZ20012716A3 (es) |
| DE (2) | DE60038823D1 (es) |
| DK (1) | DK1147112T3 (es) |
| ES (2) | ES2209825T3 (es) |
| HK (1) | HK1043116B (es) |
| HU (1) | HUP0200332A3 (es) |
| IL (1) | IL144340A0 (es) |
| NO (1) | NO20013731L (es) |
| NZ (1) | NZ512884A (es) |
| PT (1) | PT1147112E (es) |
| SK (1) | SK10692001A3 (es) |
| TR (1) | TR200102162T2 (es) |
| TW (1) | TW200300021A (es) |
| WO (1) | WO2000044755A1 (es) |
| ZA (1) | ZA200105835B (es) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| ATE386024T1 (de) * | 1997-12-31 | 2008-03-15 | Pfizer Prod Inc | Arylkondensierte azapolycyclische derivate |
| WO2001044243A2 (en) * | 1999-12-14 | 2001-06-21 | Neurosearch A/S | Novel heteroaryl-diazabicycloalkanes |
| MY145722A (en) * | 2000-04-27 | 2012-03-30 | Abbott Lab | Diazabicyclic central nervous system active agents |
| US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
| US6852721B2 (en) | 2000-05-25 | 2005-02-08 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6440970B1 (en) | 2000-05-25 | 2002-08-27 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| CA2410945A1 (en) * | 2000-07-04 | 2002-01-10 | Neurosearch A/S | Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| US6624167B1 (en) | 2000-08-04 | 2003-09-23 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| DE60202667T2 (de) * | 2001-03-02 | 2005-06-16 | Neurosearch A/S | Neue 2,5-diazabicyclo [2.2.1] heptanderivate |
| DE60203007T2 (de) * | 2001-06-01 | 2005-07-07 | Neurosearch A/S | Heteroaryl-diazabicycloalkanderivaten als cns-modulatoren |
| AR036041A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| US7390813B1 (en) | 2001-12-21 | 2008-06-24 | Xenon Pharmaceuticals Inc. | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents |
| WO2003062235A1 (en) * | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| MXPA04010966A (es) | 2002-05-07 | 2005-01-25 | Neurosearch As | Derivados novedosos de biarilo diazabiciclico. |
| US7135484B2 (en) | 2002-08-14 | 2006-11-14 | Abbott Laboratories | Azabicyclic compounds are central nervous system active agents |
| US20040242641A1 (en) * | 2003-05-27 | 2004-12-02 | Buckley Michael J. | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
| US7763618B2 (en) * | 2003-07-29 | 2010-07-27 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
| TW201038270A (en) | 2003-07-30 | 2010-11-01 | Xenon Pharmaceuticals Inc | Pyridazine derivatives and their use in the inhibition of stearoyl-CoA desaturase |
| US20050065178A1 (en) * | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| NZ546990A (en) | 2003-11-20 | 2010-03-26 | Janssen Pharmaceutica Nv | 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| SG150533A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| JP4824578B2 (ja) * | 2003-12-22 | 2011-11-30 | メモリー・ファーマシューティカルズ・コーポレイション | インドール類、１，２−ベンズイソオキサゾール類、および１，２−ベンゾイソチアゾール類、ならびにそれらの製造と使用 |
| WO2005074940A1 (en) | 2004-02-04 | 2005-08-18 | Neurosearch A/S | Diazabicyclic aryl derivatives as cholinergic receptor modulators |
| US20050171079A1 (en) * | 2004-02-04 | 2005-08-04 | Schrimpf Michael R. | Amino-substituted tricyclic derivatives and methods of use |
| US7365193B2 (en) | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
| WO2006001894A1 (en) * | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| ITMI20040954A1 (it) * | 2004-05-12 | 2004-08-12 | Univ Degli Studi Milano | Derivati del 3,6-diazabiciclo 3.1.i.eptano ad attivita' analgesica |
| WO2006003148A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Quinazolinedione derivatives as parp inhibitors |
| CN1976906B (zh) | 2004-06-30 | 2010-09-01 | 詹森药业有限公司 | 用作parp抑制剂的取代2-烷基喹唑啉酮衍生物 |
| AU2005259189B2 (en) | 2004-06-30 | 2011-04-21 | Janssen Pharmaceutica N.V. | Phthalazine derivatives as PARP inhibitors |
| AU2005284908B2 (en) | 2004-09-13 | 2011-12-08 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
| US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| CA2580857A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| MX2007003318A (es) | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| CN101084212A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途 |
| CA2580855A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| TW200626138A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
| MX2007003319A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| WO2006087305A1 (en) | 2005-02-16 | 2006-08-24 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| DE602006019561D1 (de) | 2005-02-16 | 2011-02-24 | Neurosearch As | Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin-acetylcholin-rezeptoren |
| EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| CN101305004B (zh) | 2005-12-06 | 2011-11-16 | 神经研究公司 | 新颖的二氮杂双环芳基衍生物和它们的医药用途 |
| WO2007090888A1 (en) | 2006-02-10 | 2007-08-16 | Neurosearch A/S | 3-heteroaryl- 3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists |
| CN101448828B (zh) * | 2006-02-10 | 2011-12-07 | 神经研究公司 | 作为烟碱性乙酰胆碱受体激动剂的3-杂芳基-3,9-二氮杂双环[3.3.1]壬烷衍生物 |
| EP1984366B1 (en) | 2006-02-10 | 2010-12-15 | NeuroSearch A/S | 3, 9-diazabicyclo ý3.3. 1¨nonane derivatives and their use as monoamine?neurotransmitter re-uptake inhibitors |
| CN101379063A (zh) | 2006-02-10 | 2009-03-04 | 神经研究公司 | 3,9-二氮杂双环[3.3.1]壬烷衍生物及其作为单胺神经递质再摄取抑制剂的用途 |
| WO2007093600A1 (en) * | 2006-02-14 | 2007-08-23 | Neurosearch A/S | Novel diazabicycloalkane derivatives and their medical use |
| US7855208B2 (en) | 2006-02-14 | 2010-12-21 | Neurosearch A/S | 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists |
| HRP20110917T1 (hr) | 2006-05-19 | 2012-03-31 | Abbott Laboratories | Derivati azabicikličkih alkana supstituirani fuzioniranim bicikloheterociklima aktivni u središnjem živčanom sustavu |
| US7910578B2 (en) | 2006-05-23 | 2011-03-22 | Neurosearch A/S | 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use |
| JP2009543785A (ja) * | 2006-07-14 | 2009-12-10 | メルク エンド カムパニー インコーポレーテッド | 架橋ジアゼパンオレキシン受容体アンタゴニスト |
| US8076350B2 (en) | 2006-12-22 | 2011-12-13 | Abbott Laboratories | Spirocyclic azaadamantane derivatives and methods of use |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| ES2521494T3 (es) | 2007-04-02 | 2014-11-12 | Parkinson's Institute | Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos |
| JP2010527924A (ja) * | 2007-05-18 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト |
| US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| WO2009081246A2 (en) * | 2007-12-19 | 2009-07-02 | Pfizer Inc. | Bicyclic diamines as nicotinic receptor agonists |
| AU2009228945B2 (en) | 2008-03-27 | 2013-05-02 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as tubulin polymerization inhibitors |
| JP5492183B2 (ja) | 2008-03-27 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン |
| US8148408B2 (en) * | 2008-05-09 | 2012-04-03 | Abbott Laboratories | Selective substituted pyridine ligands for neuronal nicotinic receptors |
| TW201004963A (en) * | 2008-07-03 | 2010-02-01 | Targacept Inc | Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands |
| MX2011003306A (es) * | 2008-10-14 | 2011-09-01 | Psychogenics Inc | Ligandos nicotinicos de receptor de acetilcolina y los usos de los mismos. |
| KR101925971B1 (ko) * | 2011-01-28 | 2018-12-06 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
| WO2013016160A1 (en) * | 2011-07-26 | 2013-01-31 | Merck Sharp & Dohme Corp. | NOVEL IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS mTOR INHIBITORS |
| WO2013050938A1 (en) * | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| US20150031675A1 (en) * | 2012-02-02 | 2015-01-29 | Targacept, Inc. | Diazabicyclo[3.3.1]nonanes, methods of synthesis, and uses thereof |
| CN102952134B (zh) * | 2012-12-05 | 2015-01-07 | 苏州药明康德检测检验有限责任公司 | 含二氟甲基的金雀花碱衍生物及制备方法和抗癌作用研究 |
| US10231970B2 (en) | 2014-09-30 | 2019-03-19 | NV Heterocycles | Methods of producing heteropolycycles via bis-epoxidation |
| WO2016123406A1 (en) | 2015-01-28 | 2016-08-04 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| CA3049529A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| US20180311238A1 (en) * | 2017-04-28 | 2018-11-01 | Saniona A/S | Selective Agonist Of a6 Containing nAChRs |
| CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| AR117169A1 (es) | 2018-11-28 | 2021-07-14 | Bayer Ag | (tio)amidas de piridazina como compuestos fungicidas |
| TWI840477B (en) | 2018-12-20 | 2024-05-01 | 德商拜耳廠股份有限公司 | Heterocyclyl pyridazine as fungicidal compounds |
| JP7760531B2 (ja) | 2020-05-27 | 2025-10-27 | バイエル、アクチエンゲゼルシャフト | 活性化合物の組合せ物 |
| KR20230038704A (ko) | 2020-06-18 | 2023-03-21 | 바이엘 악티엔게젤샤프트 | 활성 화합물 조합물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478939A (en) * | 1994-07-20 | 1995-12-26 | American Cyanamid Company | (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives |
| EE04057B1 (et) * | 1997-05-30 | 2003-06-16 | Neurosearch A/S | 8-asabitsüklo[3,2,1]okt-2-eeni ja -oktaani derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon |
| AU736798B2 (en) * | 1997-05-30 | 2001-08-02 | Neurosearch A/S | 9-Azabicyclo(3.3.1)non-2-ene and nonane derivatives as cholinergic ligands at nicotinic ACh receptors |
| FR2786769B1 (fr) * | 1998-12-04 | 2002-10-25 | Synthelabo | Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique |
-
2000
- 2000-01-25 PT PT00906998T patent/PT1147112E/pt unknown
- 2000-01-25 EP EP00906998A patent/EP1147112B1/en not_active Expired - Lifetime
- 2000-01-25 HK HK02102948.7A patent/HK1043116B/en not_active IP Right Cessation
- 2000-01-25 AU AU28569/00A patent/AU773795B2/en not_active Ceased
- 2000-01-25 HU HU0200332A patent/HUP0200332A3/hu unknown
- 2000-01-25 EP EP03017562A patent/EP1359152B1/en not_active Expired - Lifetime
- 2000-01-25 JP JP2000596011A patent/JP4676062B2/ja not_active Expired - Fee Related
- 2000-01-25 SK SK1069-2001A patent/SK10692001A3/sk unknown
- 2000-01-25 IL IL14434000A patent/IL144340A0/xx unknown
- 2000-01-25 DE DE60038823T patent/DE60038823D1/de not_active Expired - Lifetime
- 2000-01-25 ES ES00906998T patent/ES2209825T3/es not_active Expired - Lifetime
- 2000-01-25 WO PCT/US2000/001620 patent/WO2000044755A1/en not_active Ceased
- 2000-01-25 CZ CZ20012716A patent/CZ20012716A3/cs unknown
- 2000-01-25 CN CNA2004100974823A patent/CN1636996A/zh active Pending
- 2000-01-25 CN CN00805544A patent/CN1345320A/zh active Pending
- 2000-01-25 KR KR1020017009420A patent/KR20010101725A/ko not_active Ceased
- 2000-01-25 CA CA002361525A patent/CA2361525C/en not_active Expired - Fee Related
- 2000-01-25 NZ NZ512884A patent/NZ512884A/xx unknown
- 2000-01-25 AT AT03017562T patent/ATE394401T1/de not_active IP Right Cessation
- 2000-01-25 TR TR2001/02162T patent/TR200102162T2/xx unknown
- 2000-01-25 BR BR0007664-3A patent/BR0007664A/pt not_active IP Right Cessation
- 2000-01-25 AT AT00906998T patent/ATE253067T1/de active
- 2000-01-25 ES ES03017562T patent/ES2305373T3/es not_active Expired - Lifetime
- 2000-01-25 DE DE60006213T patent/DE60006213T2/de not_active Expired - Lifetime
- 2000-01-25 DK DK00906998T patent/DK1147112T3/da active
- 2000-01-26 CO CO00004294A patent/CO5150231A1/es unknown
- 2000-01-28 AR ARP000100393A patent/AR034538A1/es not_active Application Discontinuation
- 2000-03-01 TW TW091133012A patent/TW200300021A/zh unknown
-
2001
- 2001-07-16 ZA ZA200105835A patent/ZA200105835B/en unknown
- 2001-07-30 NO NO20013731A patent/NO20013731L/no not_active Application Discontinuation
- 2001-08-22 BG BG105836A patent/BG105836A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034538A1 (es) | Compuesto diazabiciclico n-substituido, composicion farmaceutica que lo comprende y el uso de dicho compuesto en la fabricacion de un medicamento util en el control de la liberacion de neurotransmisores y otras afecciones en mamiferos | |
| AR030421A1 (es) | Compuesto diazabiciclico n-sustituido, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para controlar la liberacion de neurotransmisor | |
| BRPI0412596A (pt) | derivados de triazolopirimidina como inibores de glicogênio sintase cinase 3 | |
| AR045930A1 (es) | Compuestos de quinoxalina | |
| AR037243A1 (es) | Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento | |
| AR035369A1 (es) | Derivados de tetrahidrobenzazepina composiciones farmaceuticas que los comprenden, el uso de dichos derivados en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos | |
| BR9909808A (pt) | Pirazolopirimidinonas inibidoras de cgmp pde5 para o tratamento da disfunção sexual | |
| AR052863A1 (es) | Compuestos de quinolina heteroaromaticos | |
| AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
| CO6180426A2 (es) | Compuesto para el tratamiento de la hepatitis b | |
| BR0213791A (pt) | Derivados de amida como inibidores de glicogênio sintase quinase 3-beta | |
| PE20060555A1 (es) | Derivados de pirrol-oxindol como moduladores del receptor de progesterona | |
| AR054799A1 (es) | Derivados de oxindol | |
| PE20010736A1 (es) | PIRAZOL-[4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE LA 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA | |
| AR053436A1 (es) | Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas | |
| AR037235A1 (es) | Derivados de sulfonamida, medicamentos que los contienen y el uso de dichos derivados para la preparacion de medicamentos | |
| CN112218631B (zh) | Atr激酶的杂环抑制剂 | |
| UY25857A1 (es) | 4-alquenil (y alquinil) oxindoles los cuales inhiben las quinasas dependientes de ciclina (cdks) | |
| MXPA05008584A (es) | Compuestos heterociclicos utiles como activadores de nurr-1. | |
| BR9813699A (pt) | Combinação eficaz para o tratamento da impotência | |
| PE20000134A1 (es) | Arilpiperazinas que tienen actividad sobre el receptor 1a de la serotonina | |
| AR037506A1 (es) | Compuestos derivados de 4-fenil-4-[1h-imidazol-2-il]piperidina sustituida, sus profarmacos, composiciones farmaceuticas que comprenden dichos compuestos derivados, y uso de dichos compuestos derivados o composiciones farmaceuticas para la elaboracion de medicamentos | |
| ES2002012A6 (es) | Procedimiento para preparar (1,2,4)triazol (1,5-c)pirimidinas e-fusionadas | |
| WO2006068954A3 (en) | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS | |
| AR045694A1 (es) | Derivados de quinazolina para el tratamiento de enfermedades proliferativas, composiciones farmaceuticas que los contienen y proceso para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |